Cargando…

SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?

INTRODUCTION: The importance of bisphosphonate drugs (BP) in preventing fractures is well known. Initial guidelines focused on early primary prevention of fracture for postmenopausal women using a BMD T-score -2.0 or lower, regardless of age (T-score < -1.5 with risk factors). In 2008, national g...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Betsy, Ettinger, Bruce, Chandra, Malini, Hui, Rita, Lo, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551829/
http://dx.doi.org/10.1210/js.2019-SAT-534
_version_ 1783424464350871552
author Yang, Betsy
Ettinger, Bruce
Chandra, Malini
Hui, Rita
Lo, Joan
author_facet Yang, Betsy
Ettinger, Bruce
Chandra, Malini
Hui, Rita
Lo, Joan
author_sort Yang, Betsy
collection PubMed
description INTRODUCTION: The importance of bisphosphonate drugs (BP) in preventing fractures is well known. Initial guidelines focused on early primary prevention of fracture for postmenopausal women using a BMD T-score -2.0 or lower, regardless of age (T-score < -1.5 with risk factors). In 2008, national guidelines focused treatment on osteoporosis (T-score < -2.5) or osteopenia (-1 > T-score > -2.5) with high fracture risk based on FRAX. This study examines whether there has been a shift in the characteristics of women initiating BP therapy for primary prevention (no previous fracture) over time from 2002 to 2013. METHOD: We included female members age within an integrated healthcare delivery system who were age 50-79y, initiated oral BP in 2002-2013, and had BMD measured within the 2 previous years. Women with fracture history (except head, fingers, toes), metastatic cancer, and advanced kidney disease were excluded. Age at BP initiation, race/ethnicity, and the proportions with normal BMD (T-score > -1), osteopenia, and osteoporosis each year and within earlier (2002-2007) and later (2008-2013) treatment eras were examined. Analyses were also stratified by race/ethnicity. RESULTS: 28,495 women age 50-79y (mean age 66y; 56% non-Hispanic White, 27% Asian, and 17% all others) met inclusion criteria. For each year from 2002-2013, the proportions of women <65y declined as the proportions >65y increased among those initiating BP. By age decade, the proportion 50-59y declined from 31% to 12%, while the proportion 60-69y and 70-79y increased from 39% to 54% and 29% to 34%, respectively, from 2002-2013. In 2013, the predominant age group initiating BP was 60-69y (54% overall; 51% in whites, 63% in Asians). During this same period, the percentage of women initiating BP who had osteoporosis progressively increased from 62% in 2002 to 79% in 2013. For whites, the overall percentage with osteoporosis was 65%, increasing from 58% in 2002 to 71% in 2013; for Asians, the percentage with osteoporosis was higher at 82%, increasing from 74% to 95% in these same years. Only among older women (70-79y) there appeared to be no temporal change (71% in 2002-2007 vs 69% in 2008-2013, p=0.1). DISCUSSION: Over time, there has been a remarkable shift in the type of woman initiating BP for primary prevention, from younger to older and from those with osteopenia to osteoporosis. By 2013, over half of the women initiating BP were 60-69y, and compared to 2002, there was a 27% higher prevalence of osteoporosis among women starting BP. Within the health plan, 13-15% of older women are Asian compared to 27% of our study population, indicating that Asians appear to be more likely to begin BP for primary prevention. Future studies should assess the impact of the observed shift in BP prescribing on fracture outcomes, focusing on the possible impact of age, race/ethnicity, and cost-effectiveness.
format Online
Article
Text
id pubmed-6551829
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65518292019-06-13 SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture? Yang, Betsy Ettinger, Bruce Chandra, Malini Hui, Rita Lo, Joan J Endocr Soc Bone and Mineral Metabolism INTRODUCTION: The importance of bisphosphonate drugs (BP) in preventing fractures is well known. Initial guidelines focused on early primary prevention of fracture for postmenopausal women using a BMD T-score -2.0 or lower, regardless of age (T-score < -1.5 with risk factors). In 2008, national guidelines focused treatment on osteoporosis (T-score < -2.5) or osteopenia (-1 > T-score > -2.5) with high fracture risk based on FRAX. This study examines whether there has been a shift in the characteristics of women initiating BP therapy for primary prevention (no previous fracture) over time from 2002 to 2013. METHOD: We included female members age within an integrated healthcare delivery system who were age 50-79y, initiated oral BP in 2002-2013, and had BMD measured within the 2 previous years. Women with fracture history (except head, fingers, toes), metastatic cancer, and advanced kidney disease were excluded. Age at BP initiation, race/ethnicity, and the proportions with normal BMD (T-score > -1), osteopenia, and osteoporosis each year and within earlier (2002-2007) and later (2008-2013) treatment eras were examined. Analyses were also stratified by race/ethnicity. RESULTS: 28,495 women age 50-79y (mean age 66y; 56% non-Hispanic White, 27% Asian, and 17% all others) met inclusion criteria. For each year from 2002-2013, the proportions of women <65y declined as the proportions >65y increased among those initiating BP. By age decade, the proportion 50-59y declined from 31% to 12%, while the proportion 60-69y and 70-79y increased from 39% to 54% and 29% to 34%, respectively, from 2002-2013. In 2013, the predominant age group initiating BP was 60-69y (54% overall; 51% in whites, 63% in Asians). During this same period, the percentage of women initiating BP who had osteoporosis progressively increased from 62% in 2002 to 79% in 2013. For whites, the overall percentage with osteoporosis was 65%, increasing from 58% in 2002 to 71% in 2013; for Asians, the percentage with osteoporosis was higher at 82%, increasing from 74% to 95% in these same years. Only among older women (70-79y) there appeared to be no temporal change (71% in 2002-2007 vs 69% in 2008-2013, p=0.1). DISCUSSION: Over time, there has been a remarkable shift in the type of woman initiating BP for primary prevention, from younger to older and from those with osteopenia to osteoporosis. By 2013, over half of the women initiating BP were 60-69y, and compared to 2002, there was a 27% higher prevalence of osteoporosis among women starting BP. Within the health plan, 13-15% of older women are Asian compared to 27% of our study population, indicating that Asians appear to be more likely to begin BP for primary prevention. Future studies should assess the impact of the observed shift in BP prescribing on fracture outcomes, focusing on the possible impact of age, race/ethnicity, and cost-effectiveness. Endocrine Society 2019-04-30 /pmc/articles/PMC6551829/ http://dx.doi.org/10.1210/js.2019-SAT-534 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Bone and Mineral Metabolism
Yang, Betsy
Ettinger, Bruce
Chandra, Malini
Hui, Rita
Lo, Joan
SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?
title SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?
title_full SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?
title_fullStr SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?
title_full_unstemmed SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?
title_short SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?
title_sort sat-534 how has bisphosphonate prescribing changed in the past decade for primary fracture?
topic Bone and Mineral Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551829/
http://dx.doi.org/10.1210/js.2019-SAT-534
work_keys_str_mv AT yangbetsy sat534howhasbisphosphonateprescribingchangedinthepastdecadeforprimaryfracture
AT ettingerbruce sat534howhasbisphosphonateprescribingchangedinthepastdecadeforprimaryfracture
AT chandramalini sat534howhasbisphosphonateprescribingchangedinthepastdecadeforprimaryfracture
AT huirita sat534howhasbisphosphonateprescribingchangedinthepastdecadeforprimaryfracture
AT lojoan sat534howhasbisphosphonateprescribingchangedinthepastdecadeforprimaryfracture